Hypolipidemic agents drug interactions: Approach to establish and assess its clinical significance. Structured review;Interacciones medicamentosas de agentes hipolipemiantes: Aproximación para establecer y valorar su relevancia clínica. Revisión estructurada

Farmacia Hospitalaria

Volumn 37, Issue 6, 2013, Pages 539-557

  Franco, D ^a,c   Henao, Y ^a   Monsalve, M ^a,c   Gutierrez F ^a,b   Hincapie, J ^a   Amariles, P ^a,c  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b Humax Pharmaceutical   (Colombia)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Drug interactions; Hypolipidemic drugs; Rhabdomyolisis

Indexed keywords

ANTILIPEMIC AGENT; CYTOCHROME P450;

DRUG INTERACTION; ENZYME INHIBITION; HUMAN; REVIEW; RHABDOMYOLYSIS; SYSTEMATIC REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FIBRIC ACIDS; FOOD-DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; RHABDOMYOLYSIS;

EID: 84890234498     PISSN: 11306343     EISSN: 21718695     Source Type: Journal    
DOI: 10.7399/FH.2013.37.6.1077     Document Type: Review

References (254)

1. Mennickent C S, Bravo D M, Calvo M C, Avello L M. [Pleiotropic effects of statins]. Rev Med Chil. 2008;136:775-82.
2. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, et al. Risk for myopathy with statin therapy in highrisk patients. Arch Intern Med. 2003;163:553-64.
3. SoRelle R. Baycol withdrawn from market. Circulation. 2001;104: E9015-6.
4. Molden E, Andersson KS, Jacobsen D. Interactions between statins and macrolide antibiotics. Tidsskr Nor Laegeforen. 2007;127: 1660-1.
5. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation. 2002;106:1024-8.
6. Amariles P, Giraldo NA, Faus MJ. Interacciones medicamentosas: aspectos generales y aproximación para establecer y utilizar su relevancia clínica. Med Clin. (Barc) 2007;129:27-35.
7. Amariles P, Giraldo NA, Faus MJ. Interacciones medicamentosas en pacientes infectados con el VIH: aproximación para establecer y evaluar su relevancia clínica. Farm Hosp. 2007;31:283-302.
8. Goldfine AB, Kaul S, Hiatt WR. Fibrates in the treatment of dyslipidemias-time for a reassessment. N Engl J Med. 2011;365:481-4.
9. Schmidt G, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med. 2007;20:411-6.
10. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288-95.
11. Ros E, Laguna JC. Tratamiento de la hipertrigliceridemia: fibratos frente a ácidos grasos omega-3. Rev Esp Cardiol. 2006;Suppl 6:52D-61D.
12. Corsini A Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005;96(suppl 9A): 44K-9.
13. Scaldaferri F, Pizzoferrato M, Ponziani FR, Gasbarrini G, Gasbarrini A. Use and indications of cholestyramine and bile acid sequestrants. Intern Emerg Med. 2013;8:205-10.
14. Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998;64:177-82.
15. Siedlik PH, Olson SC, Yang BB, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol. 1999;39:501-4.
16. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother. 2001;35:26-31.
17. Kahri AJ, Valkonen MM, Vuoristo MK, Pentikäinen PJ. Rhabdomyolysis associated with concomitant use of simvastatin and clari-thromycin. Ann Pharmacother. 2004;38:719.
18. Wagner J, Suessmair C, Pfister HW. Rhabdomyolysis caused by comedication with simvastatin and clarithromycin. J Neurol. 2009; 256:1182-3.
19. Trieu J, Emmett L, Perera C, Thanakrishnan K, Van Der Wall H. Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy. Clin Nucl Med. 2004;29:803-4.
20. Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother. 1997;31:859-63.
21. Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol. 2002;42:444-9
22. Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy. 2007;27:603-7.
23. Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J. 1998;91:202-5.
24. Tiessen RG, Lagerwey HJ, Jager GJ, Sprenger HG. [Drug interaction caused by communication problems. Rhabdomyolysis due to a combination of itraconazole and simvastatin]. Ned Tijdschr Geneeskd. 2010;154:A762.
25. Maxa JL, Melton LB, Ogu CC, Sills MN, Limanni A. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother. 2002;36:820-3.
26. Hazin R, Abuzetun JY, Suker M, Porter J. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc. 2008;100:444-6.
27. Akram K, Rao S, Parker M. A lesson for everyone in drug-drug interactions. Int J Cardiol. 2007;118:e19-20.
28. Itakura H, Vaughn D, Haller DG, O'Dwyer PJ. Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. J Urol. 2003;169:613.
29. Kahri J, Valkonen M, Bäcklund T, Vuoristo M, Kivistö KT. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur J Clin Pharmacol. 2005;60:905-7.
30. Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998;64: 58-65.
31. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1996;60:54-61.
32. Stein CA, Goel S, Ghavamian R. Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatina therapy. Invest New Drugs. 2007;25:277-8.
33. Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000;56:225-9.
34. Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 1998;46:49-53.
35. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63:332-41.
36. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2002;58:527-31.
37. Negredo E, Rey-Joly yC. [Cardiovascular risk and human immunodeficiency virus infection: A new clinical challenge]. Med Clin (Barc). 2010;135:209-11.
38. Sax PE. Strategies for management and treatment of dyslipidemia in HIV/AIDS.AIDS Care. 2006;18:149-57.
39. van Luin M, Colbers A, van Ewijk-Beneken Kolmer EW, Verweijvan Wissen CP, Schouwenberg B, Hoitsma A, da Silva HG, et al. Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2010;55:82-6.
40. Aberg JA, Rosenkranz SL, Fichtenbaum CJ, Alston BL, Brobst SW, Segal Y, et al, ACTG A5108 team. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS. 2006;20:725-9.
41. Giraldo NA, Amariles P, Gutiérrez FJ, Monsalve M, Faus MJ. Interacciones medicamentosas en pacientes infectados con el VIH: aproximación para establecer y evaluar su relevancia clínica: actualización 2009. Farm Hosp. 2010;34:90-3.
42. Amariles P, Giraldo NA, Faus MJ. Interacciones medicamentosas en pacientes infectados con el VIH: aproximación para establecer y evaluar su relevancia clínica. Farm Hosp. 2007;31:283-302.
43. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T et al; NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-77.
44. Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002;35:e111-2.
45. Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm. 2002;59:728-30.
46. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother.2001;45:3445-50.
47. Coyne KM, Boffito M, Theobald N, Asboe D. Simvastatin co-prescribed with protease inhibitors despite dangerous drug interactions. Sex Transm Infect. 2007;83:498.
48. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/Druginteraction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:570-8.
49. Busti AJ, Bain AM, Hall RG 2nd, Bedimo RG, Leff RD, Meek C, Mehvar R. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008;51:605-10.
50. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, et al, AIDS Clinical Trials Group A5108 Team. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005;39:307-12.
51. Pérez VE, Sánchez-Parra C, Villar SS. Interacciones medicamentosas de etravirina. Enferm Infecc Microbiol Clin. 2009;27:27-31.
52. Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am. 2009;38: 207-22.
53. Busse KH, Hadigan C, Chairez C, Alfaro RM, Formentini E, Kovacs JA, Penzak SR.Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. J Acquir Immune Defic Syndr. 2009;52:235-9.
54. Comunicado de la FDA sobre la seguridad de los medicamentos: La interacción entre ciertos medicamentos para el VIH o hepatitis C y los medicamentos con estatinas para reducir el colesterol, puede aumentar el riesgo de lesiones musculares. [citado 12-01-2013].FDA. Disponible en http://www.fda.gov/Drugs/DrugSafety/ucm295591.htm
55. Oates E, Dzintars K.Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient. Ann Pharmacother. 201;44:2014-7.
56. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107:32-7.
57. Mach F, Senouf D, Fontana P, Boehlen F, Reber G, Daali Y, et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest. 2005;35:476-81.
58. Júnior CV, Soeiro Ade M, Araújo LF, Jabot B, Rached F, Orii NM, et al.Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation. Arq Bras Cardiol. 2010;95:321-7.
59. Wenaweser P, Eshtehardi P, Abrecht L, Zwahlen M, Schmidlin K, Windecker S et al. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial. Thromb Haemost. 2010;104:554-62.
60. Mach F, Senouf D, Fontana P, Boehlen F, Reber G, Daali Y, et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest. 2005;35:476-81.
61. Malmström RE, Ostergren J, Jørgensen L, Hjemdahl P; CASTOR investigators. Influence of statin treatment on platelet inhibition by clopidogrel-a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. J Intern Med. 2009;266:457-66.
62. Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008;28:1483-94.
63. Riondino S, Petrini N, Donato L, Torromeo C, Tanzilli G, Pulcinelli FM, et al. Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. J Thromb Thrombolysis. 2009;28:151-5.
64. Polena S, Gupta MP, Shaikh H, Zazzali K, Coplan N, Gintautas J, et al. Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4. Proc West Pharmacol Soc. 2008;51:60-2.
65. Ayalasomayajula SP, Vaidyanathan S, Kemp C, Prasad P, Balch A, Dole WP. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin. J Clin Pharmacol. 2007;47:613-9.
66. Wenaweser P, Windecker S, Billinger M, Cook S, Togni M, Meier B, et al. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. Am J Cardiol. 2007;99:353-6.
67. Mitsios JV, Papathanasiou AI, Elisaf M, Goudevenos JA, Tselepis AD. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes. Platelets. 2005;16:287-92.
68. Poulsen TS, Vinholt P, Mickley H, Korsholm L, Kristensen SR, Damkier P. Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence. Basic Clin Pharmacol Toxicol. 2005;96:103-10.
69. Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schömig A, Kastrati A. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J. 2004;25:1898-902.
70. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC et al. Absence of interactionbetween atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med. 2004;164:2051-7.
71. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation. 2004;109: 1335-8.
72. Saw J, Topol EJ. Lack of adverse clopidogrel-atorvastatin clinical interaction. Am J Cardiol. 2004;93:669-70.
73. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, et al. Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003;108:921-4.
74. Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, et al; MITRA PLUS Study Group. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatina versus other statin therapies. Am J Cardiol. 2003;92:285-8.
75. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother. 1996;30: 1399-402.
76. tern R, Abel R, Gibson GL, Besserer J. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol. 1997;37: 1062-4.
77. Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy. 2004;24:285-90.
78. Mondillo S, Ballo P, Galderisi M. Rosuvastatin-acenocoumarol interaction. Clin Ther. 2005;27:782-4.
79. Mackay JW, Fenech ME, Myint KS.Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin. Br J Hosp Med (Lond). 2012;73:106-7.
80. Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9:59-68.
81. Dixon DL, Williams VG. Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy. 2009;29:744-8.
82. Aldridge MA, Ito MK. Fenofibrate and warfarin interaction. Pharmacotherapy. 2001;21:886-9.
83. Ascah KJ, Rock GA, Wells PS. Interaction between fenofibrate and warfarin. Ann Pharmacother. 1998;32:765-8.
84. Beringer TR. Warfarin potentiation with bezafibrate. Postgrad Med J. 1997;73:657-8.
85. Rindone JP, Keng HC. Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia. Chest. 1998;114:641-2.
86. Gan J, Chen W, Shen H, Gao L, Hong Y, Tian Y, et al. Repaglinidegemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol. 2010;70:870-80.
87. Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ et al. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanismbased inhibition of CYP2C8 in vivo. Clin Pharmacol Ther. 2008; 84:403-11.
88. Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, et al. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos. 2009;37:2359-66.
89. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. 2003;46:347-51.
90. Deng LJ, Wang F, Li HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol. 2005;61:831-6.
91. Niemi M, Neuvonen PJ, Kivistö KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther. 2001;70:439-45.
92. Kajosaari LI, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol. 2004;58:390-6.
93. KPA, Meda VS, Kucherlapati VS, Dubala A, M D, PR AV, et al. Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. Eur J Clin Pharmacol. 2012;68: 709-14.
94. Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther. 2008;84:488-96.
95. Graefe-Mody U, Huettner S, Stähle H, Ring A, Dugi KA. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther. 2010;48:367-74.
96. DiGregorio RV, Pasikhova Y. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy. 2009;29:352-6.
97. Keidar S, Guttmann H, Stam T, Fishman I, Shapira C. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Pharmacoepidemiol Drug Saf. 2007;16:1192-4.
98. Schwing W, Hustak L, Taylor HC. Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction. Endocr Pract. 2010;16:382-8.
99. DiTusa L, Luzier AB. Potential interaction between troglitazone and atorvastatin. J Clin Pharm Ther. 2000;25:279-82.
100. Prueksaritanont T, Vega JM, Zhao J, Gagliano K, Kuznetsova O, Musser B, et al. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol. 2001;41: 573-81.
101. Young MA, Lettis S, Eastmond R. Concomitant administration of cholestyramine influences the absorption of troglitazone. Br J Clin Pharmacol. 1998;45:37-40.
102. Brown KS, Armstrong IC, Wang A, Walker JR, Noveck RJ, Swearingen D, el al. Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. J Clin Pharmacol. 2010;50:554-65.
103. Kivistö KT, Neuvonen PJ. The effect of cholestyramine and activated charcoal on glipizide absorption. Br J Clin Pharmacol. 1990; 30:733-6.
104. Choi DH, Chung JH, Choi JS. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of Pglycoprotein inhibition by lovastatin. Eur J Clin Pharmacol. 2010;66:285-90.
105. Choi DH, Shin WG, Choi JS. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Eur J Clin Pharmacol. 2008;64:445-9.
106. Chiffoleau A, Trochu JN, Veyrac G, Petit T, Abadie P, Bourin M, Jolliet P. [Rhabdomyolysis in cardiac transplant recipient due to verapamil interaction with simvastatin and cyclosporin treatment]. Therapie. 2003;58:168-70.
107. Kusus M, Stapleton DD, Lertora JJ, Simon EE, Dreisbach AW. Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci. 2000;320:394-7.
108. Hu M, Mak VW, Tomlinson B. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition. J Clin Pharm Ther. 2011;36:419-25.
109. Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med. 2001;94:339-41.
110. Peces R, Pobes A. Rhabdomyolysis associated with concurrent use of simvastatina and diltiazem. Nephron. 2001;89:117-8.
111. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 1998;64:369-77.
112. You JH, Chan WK, Chung PF, Hu M, Tomlinson B. Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects. J Clin Pharmacol. 2010;50:1151-8.
113. Watanabe H, Kosuge K, Nishio S, Yamada H, Uchida S, Satoh H et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci. 2004;76:281-92.
114. Yeo KR, Yeo WW, Wallis EJ, Ramsay LE. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. Br J Clin Pharmacol. 1999;48:610-5.
115. Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000;67:267-74.
116. Lewin JJ 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatina and diltiazem. Ann Pharmacother. 2002;36: 1546-9.
117. Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005;28:223-7.
118. Preston RA, Harvey P, Herfert O, Dykstra G, Jukema JW, Sun F, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol. 2007;47:1555-69.
119. Park CG, Lee H, Choi JW, Lee SJ, Kim SH, Lim HE. Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Int J Clin Pharmacol Ther. 2010;48: 497-503.
120. Ziviani L, Da Ros L, Squassante L, Milleri S, Cugola M, Iavarone LE. The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. Br J Clin Pharmacol. 2001; 51:147-52.
121. Blaison G, Weber JC, Sachs D, Korganow AS, Martin T, Kretz JG, Pasquali JL. [Rhabdomyolysis caused by simvastatinin a patient following heart transplantation and cyclosporine therapy]. Rev Med Internet. 1992;13:61-3.
122. Segaert MF, De Soete C, Vandewiele I, Verbanck J. Drug-interaction- induced rhabdomyolysis. Nephrol Dial Transplant. 1996;11: 1846-7.
123. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coen-zyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron. 1993;65:410-3.
124. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother. 1999;33:1176-9.
125. Wong WM, Wai-Hung Shek T, Chan KH, Chau E, Lai KC. Rhabdomyolysis triggered by cytomegalovirus infection in a heart transplant patient on concomitant cyclosporine and atorvastatin therapy. J Gastroenterol Hepatol. 2004;19:952-3.
126. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 1997;62:311-21.
127. Li PK, Mak TW, Wang AY, Lee YT, Leung CB, Lui SF, Lam CW, Lai KN. The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int J Clin Pharmacol Ther. 1995;33:246-8.
128. Holdaas H, Hartmann A, Stenstrøm J, Dahl KJ, Borge M, Pfister P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol. 1995;76: 102A-6.
129. Jardine A, Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. J Clin Pharm Ther. 1999;24:397-408.
130. Park JW, Siekmeier R, Lattke P, Merz M, Mix C, Schüler S, Jaross W. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther. 2001;6:351-61.
131. Holdaas H, Hagen E, Asberg A, Lund K, Hartman A, Vaidyanathan S et al. Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. Int J Clin Pharmacol Ther. 2006;44:163-71.
132. Goldberg RB, Roth D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol. 1995;76:107A-9.
133. Park JW, Siekmeier R, Merz M, Krell B, Harder S, März W, Seidel D, Schüler S, Gross W. Pharmacokinetics of pravastatin in hearttransplant patients taking cyclosporin A. Int J Clin Pharmacol Ther. 2002;40:439-50.
134. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76:167-77.
135. Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant. 2005;5:2236-43.
136. Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol. 2002;42:222-8.
137. Basic-Jukic N, Kes P, Bubic-Filipi L, Vranjican Z. Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient. Nephrol Dial Transplant. 2010;25:2036.
138. Pisanti N, Stanziale P, Imperatore P, D'Alessandro R, De Marino V, Capone D, De Marino V. Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients. Am J Nephrol. 1998;18:199-203.
139. Jensen RA, Lal SM, Diaz-Arias A, James-Kracke M, Van Stone JC, Ross G Jr. Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. ASAIO J. 1995;41:M704-6.
140. Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol. 2006;46:328-36.
141. Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, et al. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J Clin Pharmacol. 2006;46:321-7.
142. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol. 1998;81:368-9.
143. Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000;68:122-9.
144. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozilo but not by bezafibrate. Clin Pharmacol Ther. 2001;69:340-5.
145. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75:455-63.
146. van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 1996; 240:403-4.
147. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med. 1990;112:228-30.
148. Pan WJ, Gustavson LE, Achari R, Rieser MJ, Ye X, Gutterman C, Wallin BA. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol. 2000;40:316-23.
149. Gustavson LE, Schweitzer SM, Koehne-Voss S, Achari R, Chira TO, Esslinger HU, et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite. J Clin Pharmacol. 2005;45:947-53.
150. Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol. 2004;44:1054-62.
151. Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol. 2011;51:378-88.
152. Unal A, Torun E, Sipahioglu MH, Tokgoz B, Kaya MG, Oymak O, Utas C. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Intern Med. 2008;47:1017-9.
153. Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 2003;25:459-71.
154. Buyukhatipoglu H, Sezen Y, Guntekin U, Kirhan I, Dag OF. Acute renal failure with the combined use of rosuvastatin and fenofibrate. Ren Fail. 2010;32:633-5.
155. Kosoglou T, Statkevich P, Fruchart JC, Pember LJ, Reyderman L, Cutler DL, et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin. 2004;20:1197-207
156. Gustavson LE, Schweitzer SM, Burt DA, Achari R, Rieser MJ, Edeki T, et al. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. Clin Ther. 2006;28:373-87.
157. Harvengt C, Desager JP. Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers. Eur J Clin Pharmacol. 1980;17:459-63.
158. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet. 2004;43:943-50.
159. Reyderman L, Kosoglou T, Cutler DL, Maxwell S, Statkevich P. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. Curr MedRes Opin. 2005;21:1171-9.
160. Reyderman L, Kosoglou T, Boutros T, Seiberling M, Statkevich P. Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Curr Med Res Opin. 2004;20:1493-500.
161. Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004;20:1185-95.
162. Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol. 2002;54:309-19.
163. Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol. 2006;22:141-4.
164. Reyderman L, Kosoglou T, Statkevich P, Pember L, Boutros T, Maxwell SE, et al. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Int J Clin Pharmacol Ther. 2004;42:512-8.
165. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44: 467-94.
166. Gordon RY, Becker DJ, Rader DJ. Reduced efficacy of rosuvastatin by St. John's Wort. Am J Med. 2009;122:e1-2.
167. Andrén L, Andreasson A, Eggertsen R. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol. 2007;63:913-6.
168. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther. 2001;70:518-24.
169. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol. 2004;58:56-60.
170. Lilja JJ, Kivistö KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther. 2000;68:384-90.
171. Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increa-ses serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1998;63:397-402.
172. Ando H, Tsuruoka S, Yanagihara H, Sugimoto K, Miyata M, Yamazoe Y, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 2005;60:494-7.
173. Reddy P, Ellington D, Zhu Y, Zdrojewski I, Parent SJ, Harmatz JS, et al. Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol. 2011; 72:434-41
174. Koitabashi Y, Kumai T, Matsumoto N, Watanabe M, Sekine S, Yanagida Y, Kobayashi S. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sci. 2006;78:2852-9.
175. Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer. 2008;9:232-4.
176. O'Brien SG, Meinhardt P, Bond E, Beck J, Peng B, Dutreix C, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer. 2003;89: 1855-9.
177. Triscari J, Swanson BN, Willard DA, Cohen AI, Devault A, Pan HY. Steady state serum concentrations of pravastatin and digoxin when given in combination. Br J Clin Pharmacol. 1993;36:263-5.
178. Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol. 2002;42:1352-7.
179. Garnett WR, Venitz J, Wilkens RC, Dimenna G. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med. 1994;96:84S-6.
180. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug interactions with colesevelam hydrochloride, a novel, potent lipidlowering agent. Cardiovasc Drugs Ther. 2000;14:681-90.
181. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000;40:91-8.
182. Deng S, Chen XP, Cao D, Yin T, Dai ZY, Luo J, Tang L, Li YJ. Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatina in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. Clin Ther. 2009;31:1256-63.
183. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2004;57:181-7.
184. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005;78:154-67.
185. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 2000;68:592-7.
186. Zhang W, Deng S, Chen XP, Zhou G, Xie HT, He FY, et al.Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008;30:1283-9.
187. Pennisi G, Vacante M, Russo C, Malaguarnera M. Rhabdomyolysis induced by rosuvastatin and sildenafil. South Med J. 2010;103: 1052-4.
188. Gutiérrez CA. Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis? Am Fam Physician. 2001;63:636-7.
189. Sawant RD. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. Can J Clin Pharmacol. 2009;16: e78-9.
190. Cid Conde L, Silveria Cancela D. Rabdomiolisis probablemente causada por interacción entre efalizumab y pravastatina. Farm Hosp. 2007;31:135-6.
191. Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther. 2011;90:133-42.
192. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J ClinPharmacol. 2005;45:927-34.
193. Ledl M, Hohenecker J, Francesconi C, Roots I, Bauer MF, Roden M. Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone. Diabetologia. 2005;48:1996-8.
194. Lewin JJ 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother. 2002;36: 1546-9.
195. Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia. 2008;63:656-8.
196. Yuen SL, McGarity B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med J Aust. 2003;179:172.
197. O'Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J. 2008;84:325-7.
198. Teckchandani S, Robertson S, Almond A, Donaldson K, Isles C. Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin. J R Coll Physicians Edinb. 2010;40:33-6.
199. Marot A, Morelle J, Chouinard VA, Jadoul M, Lambert M, Demoulin N. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin Belg. 2011;66:134-6.
200. Nägele H, Behrens S, Hashagen S, Azizi M. Rhabdomyolysis after addition of digitoxin to chronic simvastatin and amiodarone therapy. Drug Metabol Drug Interact. 2007;22:195-200.
201. Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, Neuvonen PJ, et al. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther. 2007; 81:679-84.
202. Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother. 2004;38:978-81.
203. de Denus S, Spinler SA. Amiodarone's role in simvastatin-associated rhabdomyolysis. Am J Health Syst Pharm. 2003;60:1791; author reply 1791-2.
204. Franz CC, Bruggisser M, Krähenbühl S, Rätz Bravo AE. Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole. Praxis (Bern 1994). 2011;100:273-84.
205. Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol. 2007;13:266-8.
206. Tufan A, Dede DS, Cavus S, Altintas ND, Iskit AB, Topeli A. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother. 2006;40:1466-9.
207. Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient. Ann Pharmacother. 2005;39:1368-9.
208. Alayli G, Cengiz K, Cantürk F, Durmu D, Akyol Y, Menek e EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005;39:1358-61.
209. Sugie M, Kuriki A, Arai D, Ichikawa H, Kawamura M. A case report of acute neuromyopathy induced by concomitant use of colchicine and bezafibrate. No To Shinkei. 2005;57:785-90.
210. Atmaca H, Sayarlioglu H, Külah E, Demircan N, Akpolat T. Rhabdomyolysis associated with gemfibrozil-colchicine therapy. Ann Pharmacother. 2002;36:1719-21.
211. Martin PD, Schneck DW, Dane AL, Warwick MJ. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Curr Med Res Opin. 2008;24:1231-5.
212. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mjörndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol. 2004;59: 879-82.
213. Andreou ER, Ledger S. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. Can J Clin Pharmacol. 2003;10:172-4.
214. Stankovic I, Vlahovic-Stipac A, Putnikovic B, Cvetkovic Z, Neskovic AN. Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis. Clin Ther. 2010;32:909-14.
215. Hsieh CY, Chen CH. Rhabdomyolysis and pancreatitis associated with coadministration of danazol 600 mg/d and lovastatin 40 mg/d. Clin Ther. 2008;30:1330-5.
216. Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther. 2010;88:223-30.
217. Karonen T, Neuvonen PJ, Backman JT. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br J Clin Pharmacol. 2012;73:257-67.
218. Karnik NS, Maldonado Jr. Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics. 2005;46:565-8.
219. Skrabal MZ, Stading JA, Monaghan MS. Rhabdomyolysis associated with simvastatin-nefazodone therapy. South Med J. 2003;96: 1034-5.
220. Thompson M, Samuels S. Rhabdomyolysis with simvastatin and nefazodone. Am J Psychiatry. 2002;159:1607.
221. Shin KH, Kim TE, Kim SE, Lee MG, Song IS, Yoon SH, et al. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol. 2011;58:492-9.
222. Allred AJ, Bowen CJ, Park JW, Peng B, Williams DD, Wire MB, et al. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol. 2011;72:321-9.
223. Gutiérrez CA. Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis? Am Fam Physician. 2001;63:636-7.
224. Sawant RD.Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin.Can J Clin Pharmacol. 2009;16: e78-9.
225. Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther. 2005;43:527-35.
226. Wu LX, Guo CX, Chen WQ, Yu J, Qu Q, Chen Y, et al. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. Br J Clin Pharmacol. 2012;73: 750-7.
227. Ayalasomayajula SP, Vaidyanathan S, Kemp C, Prasad P, Balch A, Dole WP. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin.J Clin Pharmacol. 2007;47:613-9.
228. Van Luin M, Colbers A, van Ewijk-Beneken Kolmer EW, Verweijvan Wissen CP, Et al. Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2010;55:82-6.
229. Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK. Effect ofcolesevelam on lovastatin pharmacokinetics. Ann Pharmacother. 2002;36:392-7.
230. Zhou LX, Finley DK, Hassell AE, Holtzman JL. Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers. J Pharmacol Exp Ther. 1995;273:121-7.
231. Bao T, Blackford AL, Stearns V. Effect of simvastatin on the pharmacokinetics of anastrozole. Breast Cancer Res Treat. 2012;131: 709-11.
232. Foley-Comer AJ, Young AM, Russell-Yarde F, Jordan P. Aleglitazar, a balanced PPAR/agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin. Expert Opin Investig Drugs. 2011;20:3-12.
233. Schmitt-Hoffmann AH, Roos B, Sauer J, Spickermann J, Maares J, Schoetzau A, et al. Pharmacokinetic interactions between alitretinoin and ketoconazole or simvastatin or ciclosporin A. Clin Exp Dermatol. 2011;36 Suppl 2:24-8.
234. Hang W, Deng S, Chen XP, Zhou G, Xie HT, He FY, et al. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008;30:1283-9.
235. Derks M, Abt M, Parr G, Meneses-Lorente G, Young AM, Phelan M. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opin Investig Drugs. 2010;19:1135-45.
236. Simonson SG, Martin PD, Warwick MJ, Mitchell PD, Schneck DW. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol. 2004;57:279-86.
237. Stern RH, Gibson DM, Whitfield LR. Cimetidine does not alter atorvastatina pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol. 1998;53:475-8.
238. Krishna R, Garg A, Jin B, Keshavarz SS, Bieberdorf FA, Chodakewitz J, et al. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP)inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009;67:520-6.
239. Sarich TC, Schützer KM, Dorani H, Wall U, Kalies I, Ohlsson L, et al. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. J Clin Pharmacol. 2004;44:928-34.
240. Sunkara G, Reynolds CV, Pommier F, Humbert H, Yeh C, Prasad P. Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. Curr Med Res Opin. 2007;23: 631-40.
241. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2003;59:51-6.
242. Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008;48:1323-38.
243. Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005;28: 223-7.
244. Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003;43:428-35.
245. Simard C, O'Hara GE, Prévost J, Guilbaud R, Masseé R, Turgeon J. Study of the drug-drug interaction between simvastatin and cisapride in man. Eur J Clin Pharmacol. 2001;57:229-34.
246. McDonnell CG, Malkan D, Van Pelt FD, Shorten GD.Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin.Eur J Anaesthesiol. 2003; 20:662-7.
247. Marino MR, Vachharajani NN, Hadjilambris OW. Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. J Clin Pharmacol. 2000;40:875-9.
248. Stern RH, Smithers JA, Olson SC. Atorvastatin does not produce a clinicallysignificant effect on the pharmacokinetics of terfenadine. J Clin Pharmacol. 1998; 38:753-7.
249. Meyer BH, Scholtz HE, Müller FO, Luus HG, de la Rey N, Seibert-Grafe, et al. Lack of interaction between ramipril and simvastatin. Eur J Clin Pharmacol. 1994;47:373-5.
250. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109 Suppl 1:III50-7.
251. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52C-60C.
252. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112:71-105.
253. Rowan C. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors (2010). Publicly accessible Penn Dissertations. Paper 283. Citado el 14-11-2012. Disponible en: http://repository.upenn.edu/edissertations/ 283.
254. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipidlowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565-81.